Voya Investment Management LLC Reduces Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

Voya Investment Management LLC trimmed its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 91.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,314 shares of the company’s stock after selling 315,409 shares during the quarter. Voya Investment Management LLC’s holdings in Maravai LifeSciences were worth $69,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Strs Ohio purchased a new position in Maravai LifeSciences during the first quarter worth $429,000. McAdam LLC purchased a new position in Maravai LifeSciences during the first quarter worth $31,000. Jane Street Group LLC boosted its stake in Maravai LifeSciences by 1,463.1% during the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock worth $841,000 after buying an additional 356,067 shares during the period. Ascent Group LLC bought a new stake in shares of Maravai LifeSciences during the first quarter worth $41,000. Finally, Clearline Capital LP lifted its position in shares of Maravai LifeSciences by 9.6% during the first quarter. Clearline Capital LP now owns 205,339 shares of the company’s stock worth $454,000 after purchasing an additional 18,000 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Performance

MRVI stock opened at $3.14 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. The business has a 50-day moving average price of $2.54 and a 200 day moving average price of $2.33. The company has a market capitalization of $801.83 million, a P/E ratio of -2.31 and a beta of 0.33. Maravai LifeSciences Holdings, Inc. has a 1-year low of $1.66 and a 1-year high of $8.53.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada decreased their target price on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, August 12th. Three investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and an average target price of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.